GlaxoSmithKline Czech Republic - Total Revenue Growth

Created with Highcharts 6.0.4%20042005200620072008200920102011201220132014201520162017-30-20-10010203040

GlaxoSmithKline CR`s Total Revenue Growth reached -14.6 % in 2017. This is 35.1 % less than in the previous year.

$1.99

Buy Total Revenue Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
CompanyUnit
Amgen Czech Republic %
Bayer Czech Republic %
GlaxoSmithKline Czech Republic %
Merck Czech Republic %
Novartis Czech Republic %
Pfizer Czech Republic %
Roche Czech Republic %
Sanofi-Aventis Czech Republic %
Servier Czech Republic %
Walmark %
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
... ... ... ... ...           17.8 -1.40 12.4 36.0 -5.06    
... ... ...               -2.02 -2.94 5.93 17.9 5.49    
... ... ...               -5.48 -1.59 -1.43 -14.1 -9.83    
... ...                 17.9 8.18 -1.61 4.15 2.88    
                    4.72 -0.791 3.20 15.5 15.1    
... ...                 4.32 -54.2 73.4 -8.51 -36.9    
... ... ...               -1.23 -2.83 1.33 -11.5 24.8   ...
... ... ... ...             -6.44 2.62 -9.60 -6.30 7.77    
... ... ... ... ... ... ... ... ... ... ... ... 3.49 27.6 49.6    
... ... ...               -8.22 -1.47 -9.47 18.2 -46.2